M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Sorrento wins National Institutes of Health's grant for development of small molecule Myc inhibitor
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the receipt of the non-dilutive funding for the development of the small molecule inhibitor targeting the important oncogenic transcription factor Myc.
The company received the Phase 1 Small Business Technology...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives